ACORN CAPITAL ADVISORS, LLC
13F Reported Value
ⓘ$351.8M
Holdings
22
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
ACORN CAPITAL ADVISORS, LLC disclosed 22 positions worth $351.8M in its Form 13F-HR for Q1 2026, led by $TERN (Terns Pharmaceuticals, Inc.) at 26.2% of the equity portfolio, followed by $CGON and $URGN. During the quarter the fund opened 2 new positions and exited 1 — including a new stake in $JBIO and a full exit from $ACRV. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from ACORN CAPITAL ADVISORS, LLC’s Form 13F-HR filing with the SEC under CIK 2054410.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$92.1M1,746,264 sh - 28.0#2,455
Quality
$76.6M1,130,501 sh - —
Quality
$30.1M1,673,420 sh - 52.5
Quality
$26.4M4,131,299 sh - —
Quality
$25.6M2,144,844 sh - —
Quality
$17.2M3,497,948 sh - —
Quality
$12.8M643,382 sh - —
Quality
$11.8M2,839,674 sh - —
Quality
$11.1M786,760 sh - —
Quality
$9.1M1,752,115 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Terns Pharmaceuticals, Inc.$TERN | — | $92.1M | 1,746,264 |
 CG Oncology, Inc.$CGON | 28.0#2,455 | $76.6M | 1,130,501 |
 UroGen Pharma Ltd.$URGN | — | $30.1M | 1,673,420 |
 PUMA BIOTECHNOLOGY, INC.$PBYI | 52.5 | $26.4M | 4,131,299 |
 Trevi Therapeutics, Inc.$TRVI | — | $25.6M | 2,144,844 |
 Candel Therapeutics, Inc.$CADL | — | $17.2M | 3,497,948 |
 Bicara Therapeutics Inc.$BCAX | — | $12.8M | 643,382 |
 OnKure Therapeutics, Inc.$OKUR | — | $11.8M | 2,839,674 |
 Jade Biosciences, Inc.$JBIO | — | $11.1M | 786,760 |
 Protara Therapeutics, Inc.$TARA | — | $9.1M | 1,752,115 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of ACORN CAPITAL ADVISORS, LLC's 22 positions.
Showing top 10 of 22 holdings.
Sector Allocation
Healthcare
$351.8M
Full Holdings — ACORN CAPITAL ADVISORS, LLC (Q1 2026)
All 22 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $TERN | Terns Pharmaceuticals, Inc. | $92.1M | 26.2% | +0% | — |
| 2 | $CGON | CG Oncology, Inc. | $76.6M | 21.8% | -0% | 28 |
| 3 | $URGN | UroGen Pharma Ltd. | $30.1M | 8.6% | +16% | — |
| 4 | $PBYI | PUMA BIOTECHNOLOGY, INC. | $26.4M | 7.5% | +0% | 52.5 |
| 5 | $TRVI | Trevi Therapeutics, Inc. | $25.6M | 7.3% | +0% | — |
| 6 | $CADL | Candel Therapeutics, Inc. | $17.2M | 4.9% | +36% | — |
| 7 | $BCAX | Bicara Therapeutics Inc. | $12.8M | 3.6% | +0% | — |
| 8 | $OKUR | OnKure Therapeutics, Inc. | $11.8M | 3.3% | +0% | — |
| 9 | $JBIO | Jade Biosciences, Inc. | $11.1M | 3.1% | NEW | — |
| 10 | $TARA | Protara Therapeutics, Inc. | $9.1M | 2.6% | +0% | — |
| 11 |  $VSTM | Verastem, Inc. | $7.8M | 2.2% | +0% | 40.8 |
| 12 |  $HELP | CYBIN INC. | $7.4M | 2.1% | -2% | — |
| 13 |  $LONA | LeonaBio, Inc. | $6.5M | 1.9% | +26% | — |
| 14 |  $AURA | Aura Biosciences, Inc. | $4.0M | 1.1% | +0% | — |
| 15 |  $WHWK | Whitehawk Therapeutics, Inc. | $3.9M | 1.1% | +0% | 9.6 |
| 16 |  $CRDF | Cardiff Oncology, Inc. | $2.9M | 0.8% | -10% | — |
| 17 |  $QTTB | Q32 Bio Inc. | $2.0M | 0.6% | -36% | 23.1 |
| 18 |  $KPTI | Karyopharm Therapeutics Inc. | $1.6M | 0.5% | NEW | 20.4 |
| 19 |  $JSPR | Jasper Therapeutics, Inc. | $1.2M | 0.3% | -21% | — |
| 20 |  $XFOR | X4 Pharmaceuticals, Inc | $966,583 | 0.3% | -14% | 29.3 |
| 21 |  $BCAB | BioAtla, Inc. | $865,015 | 0.3% | +12% | — |
| 22 |  $VYNE | VYNE Therapeutics Inc. | $855 | 0.0% | +0% | — |
Exited Positions (1)
$ACRV Acrivon Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for ACORN CAPITAL ADVISORS, LLC including:
Track ACORN CAPITAL ADVISORS, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for ACORN CAPITAL ADVISORS, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: ACORN CAPITAL ADVISORS, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For ACORN CAPITAL ADVISORS, LLC (SEC CIK: 2054410), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in ACORN CAPITAL ADVISORS, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.